Brief: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential For Differentiated Safety And Efficacy In Patients With PIK3CA-Driven Vascular Anomalies
19/05/2026 11:02
May 19 (Reuters) - Relay Therapeutics Inc RLAY.O: RELAY THERAPEUTICS ANNOUNCES INITIAL CLINICAL DATA DEMONSTRATING THAT ZOVEGALISIB HAS POTENTIAL FOR DIFFERENTIATED SAFETY AND EFFICACY IN PATIENTS WITH PIK3CA-DRIVEN VASCULAR ANOMALIES RELAY THERAPEUTICS INC - NO PATIENTS DISCONTINUED TREATMENT DUE TO ADVERSE EVENTS RELAY THERAPEUTICS INC - 89% INVESTIGATOR-REPORTED AND 79% PATIENT-REPORTED CLINICAL IMPROVEMENT AT WEEK 12 RELAY THERAPEUTICS INC - 60% OF PATIENTS ACHIEVE VOLUMETRIC RESPONSE AT 12 WEEKS AS OF APRIL 15, 2026 Source text: ID:nGNXMJmdL Further company coverage: RLAY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relay Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Moderna, Kontoor Brands, Ralph Lauren
U.S. STOCKS ON THE MOVE- Intuit, Deere, Advance Auto Parts
U.S. STOCKS ON THE MOVE-Keysight Technologies, Relay Therapeutics, Ralph Lauren
Relay Therapeutics gains after $275 mln equity raise
Brief: Relay Therapeutics Announces Pricing Of Public Offering Of Common Stock